Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Administration and Management

Interview with Danielle Roberts, PA-C: Sequencing of Bispecific Antibodies and CAR T-Cell Therapies

Interview with Danielle Roberts, PA-C: Onboarding APPs New to Multiple Myeloma Practice

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

A Review of Unmet Needs and Ways to Provide Optimal Care in Multiple Myeloma

Make it Happen: To Better Serve the Multiple Myeloma Community

A Focus on Relapsed Multiple Myeloma

Disparities in Healthcare

International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

Transfusion Clinique et Biologique

Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

Clinical Pharmacology and Therapeutics

A novel two-part mixture model for the incidence and time course of cytokine release syndrome after elranatamab dosing in multiple myeloma patients

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Presse Medicale

Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma

Clinical Cancer Research

Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory multiple myeloma

Multiple Myeloma Resource Center

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Administration and Management

A Review of Unmet Needs and Ways to Provide Optimal Care in Multiple Myeloma

Make it Happen: To Better Serve the Multiple Myeloma Community

A Focus on Relapsed Multiple Myeloma

Disparities in Healthcare

International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

Transfusion Clinique et Biologique

Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

Clinical Pharmacology and Therapeutics

A novel two-part mixture model for the incidence and time course of cytokine release syndrome after elranatamab dosing in multiple myeloma patients

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Presse Medicale

Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma

Clinical Cancer Research

Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory multiple myeloma

Treatment of Intermediate Risk Smoldering Myeloma

Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy

Single Solitary Plasmacytoma to Active Myeloma